These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 31489759

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders.
    Birschmann I, Klamroth R, Eichler H, Schenk J, Kirchmaier CM, Halimeh S.
    Haemophilia; 2013 Sep; 19(5):679-85. PubMed ID: 23647644
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Recombinant factor VIIa (NovoSeven). A review of current and possible future indications].
    Heuer L, Blumenberg D.
    Anaesthesist; 2002 May; 51(5):388-99. PubMed ID: 12125311
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.
    Parameswaran R, Shapiro AD, Gill JC, Kessler CM, HTRS Registry Investigators.
    Haemophilia; 2005 Mar; 11(2):100-6. PubMed ID: 15810910
    [Abstract] [Full Text] [Related]

  • 9. Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg⁻¹) rFVIIa doses across clinical trials and registries.
    Shapiro AD, Neufeld EJ, Blanchette V, Salaj P, Gut RZ, Cooper DL.
    Haemophilia; 2014 Jan; 20(1):e23-31. PubMed ID: 24354484
    [Abstract] [Full Text] [Related]

  • 10. Experience of recombinant activated factor VII usage during surgery in patients with haemophilia with inhibitors.
    Polyanskaya T, Zorenko V, Karpov E, Sampiev M, Mishin G, Vasiliev D.
    Haemophilia; 2012 Nov; 18(6):997-1002. PubMed ID: 22672066
    [Abstract] [Full Text] [Related]

  • 11. Dose optimization of recombinant factor VIIa in the treatment of acute bleeding in haemophilia-associated inhibitors.
    Seremetis S.
    Blood Coagul Fibrinolysis; 2003 Jun; 14 Suppl 1():S29-30. PubMed ID: 14567532
    [Abstract] [Full Text] [Related]

  • 12. Immune tolerance induction: a role for recombinant activated factor VII (rFVIIa)?
    Brackmann HH, Effenberger W, Hess L, Schwaab R, Oldenburg J.
    Eur J Haematol Suppl; 1998 Jun; 63():18-23. PubMed ID: 9882928
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency.
    Scharrer I.
    Haemophilia; 1999 Jul; 5(4):253-9. PubMed ID: 10469179
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Safety and effectiveness of room temperature stable recombinant factor VIIa in patients with haemophilia A or B and inhibitors: Results of a multinational, prospective, observational study.
    Kavakli K, Demartis F, Karimi M, Eshghi P, Neme D, Chambost H, Sommer L, Zak M, Benson G.
    Haemophilia; 2017 Jul; 23(4):575-582. PubMed ID: 28440004
    [Abstract] [Full Text] [Related]

  • 17. Cost and effectiveness of treatments for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Korea.
    You CW, Lee SY, Park SK.
    Haemophilia; 2009 Jan; 15(1):217-26. PubMed ID: 18754800
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
    Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, Gilchrist GS, Gill JC, Glader B, Hoots WK, Kisker CT, Lusher JM, Rosenfield CG, Shapiro AD, Smith H, Taft E.
    Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
    [Abstract] [Full Text] [Related]

  • 20. Eptacog beta for the management of patients with haemophilia A and B with inhibitors: A European perspective.
    Miesbach W, Carcao M, Mahlangu J, Dargaud Y, Jimenez-Yuste V, Hermans C.
    Haemophilia; 2024 Mar; 30(2):257-266. PubMed ID: 38317441
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.